

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES



---

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

---

## Editor-in-Chief

**Prof. Terken BAYDAR, Ph.D., E.R.T.**

orcid.org/0000-0002-5497-9600

Hacettepe University, Faculty of Pharmacy,

Department of Toxicology, Ankara, TURKEY

tbaydar@hacettepe.edu.tr

---

## Associate Editors

**Prof. Samiye YABANOĞLU ÇİFTÇİ, Ph.D.**

orcid.org/0000-0001-5467-0497

Hacettepe University, Faculty of Pharmacy,

Department of Biochemistry, Ankara, TURKEY

samiye@hacettepe.edu.tr

**Prof. Pınar ERKEKOĞLU, Ph.D., E.R.T.**

orcid.org/0000-0003-4713-7672

Hacettepe University, Faculty of Pharmacy,

Department of Toxicology, Ankara, TURKEY

erkekp@hacettepe.edu.tr

---

## Editorial Board

**Prof. Fernanda BORGES, Ph.D.**

orcid.org/0000-0003-1050-2402

Porto University, Faculty of Sciences, Department of  
Chemistry and Biochemistry, Porto, PORTUGAL

fborges@fc.up.pt

**Prof. Bezhan CHANKVETADZE, Ph.D.**

orcid.org/0000-0003-2379-9815

Ivane Javakhishvili Tbilisi State University, Institute  
of Physical and Analytical Chemistry, Tbilisi,  
GEORGIA

jpba\_bezhan@yahoo.com

**Prof. Dietmar FUCHS, Ph.D.**

orcid.org/0000-0003-1627-9563

Innsbruck Medical University, Center for Chemistry  
and Biomedicine, Institute of Biological Chemistry,  
Biocenter, Innsbruck, AUSTRIA

dietmar.fuchs@i-med.ac.at

**Prof. Satyajit D. Sarker, Ph.D.**

orcid.org/0000-0003-4038-0514

Liverpool John Moores University, Liverpool,  
UNITED KINGDOM

S.Sarker@ljmu.ac.uk

**Prof. Luciano SASO, Ph.D.**

orcid.org/0000-0003-4530-8706

Sapienza University, Faculty of Pharmacy  
and Medicine, Department of Physiology and  
Pharmacology "Vittorio Ersamer", Rome, ITALY

luciano.saso@uniroma1.it

**Prof. Rob VERPOORTE, Ph.D.**

orcid.org/0000-0001-6180-1424

Leiden University, Natural Products Laboratory,  
Leiden, NETHERLANDS

verpoort@chem.leidenuniv.nl

---

## Advisory Board

**Prof. Nurettin ABACIOĞLU, Ph.D.**

Kyrenia University, Faculty of Pharmacy,  
Department of Pharmacology, Girne, TRNC,  
CYPRUS

**Prof. Kadriye BENKLİ, Ph.D.**

İstinye University, Faculty of Pharmacy,  
Department of Pharmaceutical Chemistry, İstanbul,  
TURKEY

**Prof. Arzu BEŞİKCİ, Ph.D.**

Ankara University, Faculty of Pharmacy,  
Department of Pharmacology, Ankara, TURKEY

**Prof. Erem BİLENSOY, Ph.D.**

Hacettepe University, Faculty of Pharmacy, Department  
of Pharmaceutical Technology, Ankara, TURKEY

**Prof. Hermann BOLT, Ph.D.**

Dortmund University, Leibniz Research Centre, Institute  
of Occupational Physiology, Dortmund, GERMANY

**Prof. Erdal CEVHER, Ph.D.**

İstanbul University Faculty of Pharmacy,  
Department of Pharmaceutical Technology,  
İstanbul, TURKEY

**Prof. Nevin ERK, Ph.D.**

Ankara University, Faculty of Pharmacy,  
Department of Analytical Chemistry, Ankara,  
TURKEY

**Prof. Jean-Alain FEHRENTZ, Ph.D.**

Montpellier University, Faculty of Pharmacy,  
Institute of Biomolecules Max Mousseron,  
Montpellier, FRANCE

**Prof. Joerg KREUTER, Ph.D.**

Johann Wolfgang Goethe University, Faculty of  
Pharmacy, Institute of Pharmaceutical Technology,  
Frankfurt, GERMANY

**Prof. Christine LAFFORGUE, Ph.D.**

Paris-Sud University, Faculty of Pharmacy,  
Department of Dermopharmacology and  
Cosmetology, Paris, FRANCE

**Prof. Şule APİKOĞLU RABUŞ, Ph.D.**

Marmara University, Faculty of Pharmacy,  
Department of Clinical Pharmacy, İstanbul,  
TURKEY

**Prof. Robert RAPOPORT, Ph.D.**

Cincinnati University, Faculty of Pharmacy,  
Department of Pharmacology and Cell Biophysics,  
Cincinnati, USA

**Prof. Wolfgang SADEE, Ph.D.**

Ohio State University, Center for  
Pharmacogenomics, Ohio, USA

**Prof. Hildebert WAGNER, Ph.D.**

Ludwig-Maximilians University, Center for  
Pharmaceutical Research, Institute of Pharmacy,  
Munich, GERMANY

**Assoc. Prof. Hande SİPAHİ, Ph.D.**

Yeditepe University, Faculty of Pharmacy,  
Department of Toxicology, İstanbul, TURKEY

**Prof. İpek SÜNTAR, Ph.D.**

Gazi University, Faculty of Pharmacy, Department  
of Pharmacognosy, Ankara, TURKEY

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

## Baş Editör

**Terken BAYDAR , Prof. Dr. E.R.T.**  
orcid.org/0000-0002-5497-9600  
Hacettepe Üniversitesi, Eczacılık Fakültesi,  
Toksikoloji Anabilim Dalı, Ankara, TÜRKİYE  
tbaydar@hacettepe.edu.tr

## Yardımcı Editörler

**Samiye YABANOĞLU ÇİFTÇİ, Prof. Dr.**  
orcid.org/0000-0001-5467-0497  
Hacettepe Üniversitesi, Eczacılık Fakültesi ,  
Biyokimya Anabilim Dalı, Ankara, TÜRKİYE  
samiye@hacettepe.edu.tr

**Pınar ERKEKOĞLU, Prof. Dr. E.R.T.**  
orcid.org/0000-0003-4713-7672  
Hacettepe Üniversitesi, Eczacılık Fakültesi,  
Toksikoloji Anabilim Dalı, Ankara, TÜRKİYE  
erkekp@hacettepe.edu.tr

## Editörler Kurulu

**Fernanda BORGES, Prof. Dr.**  
orcid.org/0000-0003-1050-2402  
Porto Üniversitesi, Fen Fakültesi, Kimya ve  
Biyokimya Anabilim Dalı, Porto, PORTEKİZ  
fborges@fc.up.pt

**Bezhan CHANKVETADZE, Prof. Dr.**  
orcid.org/0000-0003-2379-9815  
Ivane Javakhishvili Tiflis Devlet Üniversitesi, Fiziksel  
ve Analitik Kimya Enstitüsü, Tiflis, GÜRCİSTAN  
jpba\_bezhan@yahoo.com

**Dietmar FUCHS, Prof. Dr.**  
orcid.org/0000-0003-1627-9563  
Innsbruck Tıp Üniversitesi, Kimya ve Biyotıp Merkezi,  
Biyolojik Kimya Enstitüsü, Biocenter, Innsbruck,  
AVUSTURYA  
dietmar.fuchs@i-med.ac.at

**Satyajit D. Sarker, Prof. Dr.**  
orcid.org/0000-0003-4038-0514  
Liverpool John Moores Üniversitesi, Liverpool,  
BİRLEŞİK KRALLIK  
S.Sarker@ljmu.ac.uk

**Luciano SASO, Prof. Dr.**  
orcid.org/0000-0003-4530-8706  
Sapienza Üniversitesi, Eczacılık ve Tıp Fakültesi,  
Fizyoloji ve Farmakoloji Anabilim Dalı "Vittorio  
Erspamer", Roma, İTALYA  
luciano.saso@uniroma1.it

**Rob VERPOORTE, Prof. Dr.**  
orcid.org/0000-0001-6180-1424  
Leiden Üniversitesi, Doğal Ürünler Laboratuvarı,  
Leiden, HOLLANDA  
verpoort@chem.leidenuniv.nl

## Danışma Kurulu

**Nurettin ABACIOĞLU, Prof. Dr.**  
Girne Üniversitesi, Eczacılık Fakültesi, Farmakoloji  
Anabilim Dalı, Girne, TRNC, KIBRIS

**Kadriye BENKLİ, Prof. Dr.**  
İstinye Üniversitesi, Eczacılık Fakültesi, Farmasötik  
Kimya Anabilim Dalı, İstanbul, TÜRKİYE

**Arzu BEŞİKÇİ, Prof. Dr.**  
Ankara Üniversitesi, Eczacılık Fakültesi,  
Farmakoloji Anabilim Dalı, Ankara, TÜRKİYE

**Erem BİLENSOY, Prof. Dr.**  
Hacettepe Üniversitesi, Eczacılık Fakültesi,  
Farmasötik Anabilim Dalı, Ankara, TÜRKİYE

**Hermann BOLT, Prof. Dr.**  
Dortmund Üniversitesi, Leibniz Araştırma Merkezi,  
Mesleki Fizyoloji Enstitüsü, Dortmund,  
ALMANYA

**Erdal CEVHER, Prof. Dr.**  
İstanbul Üniversitesi Eczacılık Fakültesi,  
Farmasötik Anabilim Dalı, İstanbul, TÜRKİYE

**Nevin ERK, Prof. Dr.**  
Ankara Üniversitesi, Eczacılık Fakültesi, Analitik  
Kimya Anabilim Dalı, Ankara, TÜRKİYE

**Jean-Alain FEHRENTZ, Prof. Dr.**  
Montpellier Üniversitesi, Eczacılık Fakültesi,  
Biyomoleküller Enstitüsü Max Mousseron,  
Montpellier, FRANSA

**Joerg KREUTER, Prof. Dr.**  
Johann Wolfgang Goethe Üniversitesi, Eczacılık  
Fakültesi, Farmasötik Teknoloji Enstitüsü,  
Frankfurt, ALMANYA

**Christine LAFFORGUE, Prof. Dr.**  
Paris-Sud Üniversitesi, Eczacılık Fakültesi,  
Dermofarmakoloji ve Kozmetoloji Bölümü, Paris,  
FRANSA

**Şule APIKOĞLU RABUŞ, Prof. Dr.**  
Marmara Üniversitesi, Eczacılık Fakültesi, Klinik  
Eczacılık Anabilim Dalı, İstanbul, TÜRKİYE

**Robert RAPOPORT, Prof. Dr.**  
Cincinnati Üniversitesi, Eczacılık Fakültesi,  
Farmakoloji ve Hücre Biyofiziği Bölümü, Cincinnati,  
ABD

**Wolfgang SADEE, Prof. Dr.**  
Ohio Eyalet Üniversitesi, Farmakogenomik  
Merkezi, Ohio, ABD

**Hildebert WAGNER, Prof. Dr.**  
Ludwig-Maximilians Üniversitesi, Farmasötik  
Araştırma Merkezi, Eczacılık Enstitüsü, Münih,  
ALMANYA

**Hande SİPAHİ, Doç. Dr.**  
Yeditepe Üniversitesi, Eczacılık Fakültesi,  
Toksikoloji Anabilim Dalı, İstanbul, TÜRKİYE

**İpek SÜNTAR, Prof. Dr.**  
Gazi Üniversitesi, Eczacılık Fakültesi,  
Farmakognozi Anabilim Dalı, Ankara, TÜRKİYE

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

## AIMS AND SCOPE

The Turkish Journal of Pharmaceutical Sciences is the only scientific periodical publication of the Turkish Pharmacists' Association and has been published since April 2004.

Turkish Journal of Pharmaceutical Sciences journal is regularly published 6 times in a year (February, April, June, August, October, December). The issuing body of the journal is Galenos Yayınevi/Publishing House level.

The aim of Turkish Journal of Pharmaceutical Sciences is to publish original research papers of the highest scientific and clinical value at an international level. The target audience includes specialists and professionals in all fields of pharmaceutical sciences.

The editorial policies are based on the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2013, archived at <http://www.icmje.org/>) rules.

### Editorial Independence

Turkish Journal of Pharmaceutical Sciences is an independent journal with independent editors and principles and has no commercial relationship with the commercial product, drug or pharmaceutical company regarding decisions and review processes upon articles.

### ABSTRACTED/INDEXED IN

PubMed Central  
Web of Science-Emerging Sources Citation Index (ESCI)  
SCOPUS SJR  
TÜBİTAK/ULAKBİM TR Dizin  
Directory of Open Access Journals (DOAJ)  
ProQuest  
Chemical Abstracts Service (CAS)  
EBSCO  
EMBASE  
GALE  
Index Copernicus  
Analytical Abstracts  
International Pharmaceutical Abstracts (IPA)  
Medicinal & Aromatic Plants Abstracts (MAPA)  
British Library  
CSIR INDIA  
GOALI  
Hinari  
OARE  
ARDI  
AGORA  
Türkiye Atıf Dizini  
Türk Medline  
UDL-EDGE  
J- Gate  
Ideonline  
ROOTINDEXING  
CABI

### OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/>. By "open access" to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

### CORRESPONDENCE ADDRESS

All correspondence should be directed to the Turkish Journal of Pharmaceutical Sciences editorial board;

Post Address: Turkish Pharmacists' Association, Mustafa Kemal Mah 2147.Sok No:3 06510 Çankaya/Ankara, TURKEY  
Phone: +90 (312) 409 81 00  
Fax: +90 (312) 409 81 09  
Web Page: <http://turkjps.org>  
E-mail: [teb@teb.org.tr](mailto:teb@teb.org.tr)

### PERMISSIONS

Requests for permission to reproduce published material should be sent to the publisher.

Publisher: Erkan Mor  
Address: Molla Gürani Mah. Kaçamak Sok. 21/1 Fındıkzade, Fatih, İstanbul, Turkey  
Telephone: +90 212 621 99 25  
Fax: +90 212 621 99 27  
Web page: <http://www.galenos.com.tr/en>  
E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr)

### ISSUING BODY CORRESPONDING ADDRESS

Issuing Body : Galenos Yayınevi  
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1, 34093 İstanbul, Turkey  
Phone: +90 212 621 99 25 Fax: +90 212 621 99 27  
E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr)

### MATERIAL DISCLAIMER

The author(s) is (are) responsible for the articles published in the JOURNAL. The editor, editorial board and publisher do not accept any responsibility for the articles.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



Galenos Publishing House  
Owner and Publisher  
Derya Mor  
Erkan Mor  
Publication Coordinator  
Burak Sever  
Web Coordinators  
Fuat Hocalar  
Turgay Akpınar  
Graphics Department  
Ayda Alaca  
Çiğdem Birinci  
Gülşah Özgül  
Finance Coordinator  
Sevinç Çakmak

Project Coordinators  
Proje Koordinatörü  
Duygu Yıldırım  
Gamze Aksoy  
Gülşay Akın  
Hatice Sever  
Melike Eren  
Özlem Çelik  
Pınar Akpınar  
Rabia Palazoğlu  
Saliha Tuğçe Evin  
Research&Development  
Mert Can Köse  
Mevlûde Özlem Akgüney

Publisher Contact  
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1  
34093 İstanbul, Turkey  
Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27  
E-mail: [info@galenos.com.tr](mailto:info@galenos.com.tr) | [yayin@galenos.com.tr](mailto:yayin@galenos.com.tr)  
Web: [www.galenos.com.tr](http://www.galenos.com.tr) | Publisher Certificate Number: 14521  
Printing at: Özgün Basım Tanıtım San. Tic. Ltd. Şti.  
Yeşilce Mah. Aytekin Sok. Oto Sanayi Sitesi No: 21 Kat: 2  
Seyrantepe Sanayi, Kağıthane, İstanbul, Türkiye  
Telefon/Phone: +90 (212) 280 00 09 Sertifika No: 48150  
Printing Date: October 2020  
ISSN: 1304-530X  
International scientific journal published quarterly.

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

## INSTRUCTIONS TO AUTHORS

Turkish Journal of Pharmaceutical Sciences journal is published 6 times (February, April, June, August, October, December) per year and publishes the following articles:

- Research articles
- Reviews (only upon the request or consent of the Editorial Board)
- Preliminary results/Short communications/Technical notes/Letters to the Editor in every field of pharmaceutical sciences.

The publication language of the journal is English.

The Turkish Journal of Pharmaceutical Sciences does not charge any article submission or processing charges.

A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere.

The Journal should be abbreviated as "Turk J Pharm Sci" when referenced.

The scientific and ethical liability of the manuscripts belongs to the authors and the copyright of the manuscripts belongs to the Journal. Authors are responsible for the contents of the manuscript and accuracy of the references. All manuscripts submitted for publication must be accompanied by the Copyright Transfer Form [copyright transfer]. Once this form, signed by all the authors, has been submitted, it is understood that neither the manuscript nor the data it contains have been submitted elsewhere or previously published and authors declare the statement of scientific contributions and responsibilities of all authors.

Experimental, clinical and drug studies requiring approval by an ethics committee must be submitted to the JOURNAL with an ethics committee approval report including approval number confirming that the study was conducted in accordance with international agreements and the Declaration of Helsinki (revised 2013) (<http://www.wma.net/en/30publications/10policies/b3/>). The approval of the ethics committee and the fact that informed consent was given by the patients should be indicated in the Materials and Methods section. In experimental animal studies, the authors should indicate that the procedures followed were in accordance with animal rights as per the Guide for the Care and Use of Laboratory Animals (<http://oacu.od.nih.gov/regs/guide/guide.pdf>) and they should obtain animal ethics committee approval.

Authors must provide disclosure/acknowledgment of financial or material support, if any was received, for the current study.

If the article includes any direct or indirect commercial links or if any institution provided material support to the study, authors must state in the cover letter that they have no relationship with the commercial product, drug, pharmaceutical company, etc. concerned; or specify the type of relationship (consultant, other agreements), if any.

Authors must provide a statement on the absence of conflicts of interest among the authors and provide authorship contributions.

All manuscripts submitted to the journal are screened for plagiarism using the 'iThenticate' software. Results indicating plagiarism may result in manuscripts being returned or rejected.

### The Review Process

This is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation

are sent for external peer review, and the Editor-in-Chief assigns an Associate Editor. The Associate Editor sends the manuscript to at least two reviewers (internal and/or external reviewers). The Associate Editor recommends a decision based on the reviewers' recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

The scientific board guiding the selection of the papers to be published in the Journal consists of elected experts of the Journal and if necessary, selected from national and international authorities. The Editor-in-Chief, Associate Editors may make minor corrections to accepted manuscripts that do not change the main text of the paper.

In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the Journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. The Journal accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.

The Editorial Policies and General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2013, archived at <http://www.icmje.org/>).

Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:

CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (<http://www.consort-statement.org/>);

PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (<http://www.prisma-statement.org/>);

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (<http://www.stard-statement.org/>);

STROBE statement, a checklist of items that should be included in reports of observational studies (<http://www.strobe-statement.org/>);

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).

## GENERAL GUIDELINES

Manuscripts can only be submitted electronically through the Journal Agent website (<http://journalagent.com/tjps/>) after creating an account. This system allows online submission and review.

---

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

---

## INSTRUCTIONS TO AUTHORS

**Format:** Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.

**Abbreviations:** Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.

**Cover letter:** The cover letter should include statements about manuscript type, single-Journal submission affirmation, conflict of interest statement, sources of outside funding, equipment (if applicable), for original research articles.

### ETHICS COMMITTEE APPROVAL

The editorial board and our reviewers systematically ask for ethics committee approval from every research manuscript submitted to the Turkish Journal of Pharmaceutical Sciences. If a submitted manuscript does not have ethical approval, which is necessary for every human or animal experiment as stated in international ethical guidelines, it must be rejected on the first evaluation.

Research involving animals should be conducted with the same rigor as research in humans; the Turkish Journal of Pharmaceutical Sciences asks original approval document to show implements the 3Rs principles. If a study does not have ethics committee approval or authors claim that their study does not need approval, the study is consulted to and evaluated by the editorial board for approval.

### SIMILARITY

The Turkish Journal of Pharmaceutical Sciences is routinely looking for similarity index score from every manuscript submitted before evaluation by the editorial board and reviewers. The journal uses iThenticate plagiarism checker software to verify the originality of written work. There is no acceptable similarity index; but, exceptions are made for similarities less than 15 %.

### REFERENCES

Authors are solely responsible for the accuracy of all references.

**In-text citations:** References should be indicated as a superscript immediately after the period/full stop of the relevant sentence. If the author(s) of a reference is/are indicated at the beginning of the sentence, this reference should be written as a superscript immediately after the author's name. If relevant research has been conducted in Turkey or by Turkish investigators, these studies should be given priority while citing the literature.

Presentations presented in congresses, unpublished manuscripts, theses, Internet addresses, and personal interviews or experiences should not be indicated as references. If such references are used, they should be indicated in parentheses at the end of the relevant sentence in the text, without reference number and written in full, in order to clarify their nature.

**References section:** References should be numbered consecutively in the order in which they are first mentioned in the text. All authors should be listed regardless of number. The titles of Journals should be abbreviated according to the style used in the Index Medicus.

Reference Format

**Journal:** Last name(s) of the author(s) and initials, article title, publication title and its original abbreviation, publication date, volume, the inclusive page numbers. Example: Collin JR, Rathbun JE. Involuntary entropion: a review with evaluation of a procedure. Arch Ophthalmol. 1978;96:1058-1064.

**Book:** Last name(s) of the author(s) and initials, book title, edition, place of publication, date of publication and inclusive page numbers of the extract cited.

Example: Herbert L. The Infectious Diseases (1st ed). Philadelphia; Mosby Harcourt; 1999;11;1-8.

**Book Chapter:** Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.

Example: O'Brien TP, Green WR. Periocular Infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases (4th ed). Philadelphia; W.B. Saunders Company;1998:1273-1278.

**Books in which the editor and author are the same person:** Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece. Example: Solcia E, Capella C, Kloppel G. Tumors of the exocrine pancreas. In: Solcia E, Capella C, Kloppel G, eds. Tumors of the Pancreas. 2nd ed. Washington: Armed Forces Institute of Pathology; 1997:145-210.

### TABLES, GRAPHICS, FIGURES, AND IMAGES

All visual materials together with their legends should be located on separate pages that follow the main text.

**Images:** Images (pictures) should be numbered and include a brief title. Permission to reproduce pictures that were published elsewhere must be included. All pictures should be of the highest quality possible, in JPEG format, and at a minimum resolution of 300 dpi.

**Tables, Graphics, Figures:** All tables, graphics or figures should be enumerated according to their sequence within the text and a brief descriptive caption should be written. Any abbreviations used should be defined in the accompanying legend. Tables in particular should be explanatory and facilitate readers' understanding of the manuscript, and should not repeat data presented in the main text.

### MANUSCRIPT TYPES

#### Original Articles

Clinical research should comprise clinical observation, new techniques or laboratories studies. Original research articles should include title, structured abstract, key words relevant to the content of the article, introduction, materials and methods, results, discussion, study limitations, conclusion references, tables/figures/images and acknowledgement sections. Title, abstract and key words should be written in both Turkish and English. The manuscript should be formatted in accordance with the above-mentioned guidelines and should not exceed 16 A4 pages.

**Title Page:** This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:



# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

## INSTRUCTIONS TO AUTHORS

1. Title of the manuscript (Turkish and English), as concise and explanatory as possible, including no abbreviations, up to 135 characters
2. Short title (Turkish and English), up to 60 characters
3. Name(s) and surname(s) of the author(s) (without abbreviations and academic titles) and affiliations
4. Name, address, e-mail, phone and fax number of the corresponding author
5. The place and date of scientific meeting in which the manuscript was presented and its abstract published in the abstract book, if applicable

**Abstract:** A summary of the manuscript should be written in both Turkish and English. References should not be cited in the abstract. Use of abbreviations should be avoided as much as possible; if any abbreviations are used, they must be taken into consideration independently of the abbreviations used in the text. For original articles, the structured abstract should include the following sub-headings:

**Objectives:** The aim of the study should be clearly stated.

**Materials and Methods:** The study and standard criteria used should be defined; it should also be indicated whether the study is randomized or not, whether it is retrospective or prospective, and the statistical methods applied should be indicated, if applicable.

**Results:** The detailed results of the study should be given and the statistical significance level should be indicated.

**Conclusion:** Should summarize the results of the study, the clinical applicability of the results should be defined, and the favorable and unfavorable aspects should be declared.

**Keywords:** A list of minimum 3, but no more than 5 key words must follow the abstract. Key words in English should be consistent with "Medical Subject Headings (MESH)" ([www.nlm.nih.gov/mesh/MBrowser.html](http://www.nlm.nih.gov/mesh/MBrowser.html)). Turkish key words should be direct translations of the terms in MESH.

Original research articles should have the following sections:

**Introduction:** Should consist of a brief explanation of the topic and indicate the objective of the study, supported by information from the literature.

**Materials and Methods:** The study plan should be clearly described, indicating whether the study is randomized or not, whether it is retrospective or prospective, the number of trials, the characteristics, and the statistical methods used.

**Results:** The results of the study should be stated, with tables/figures given in numerical order; the results should be evaluated according to the statistical analysis methods applied. See General Guidelines for details about the preparation of visual material.

**Discussion:** The study results should be discussed in terms of their favorable and unfavorable aspects and they should be compared with the literature. The conclusion of the study should be highlighted.

**Study Limitations:** Limitations of the study should be discussed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

**Conclusion:** The conclusion of the study should be highlighted.

**Acknowledgements:** Any technical or financial support or editorial contributions (statistical analysis, English/Turkish evaluation) towards the study should appear at the end of the article.

**References:** Authors are responsible for the accuracy of the references. See General Guidelines for details about the usage and formatting required.

### Review Articles

Review articles can address any aspect of clinical or laboratory pharmaceuticals. Review articles must provide critical analyses of contemporary evidence and provide directions of or future research. Most review articles are commissioned, but other review submissions are also welcome. Before sending a review, discussion with the editor is recommended.

Reviews articles analyze topics in depth, independently and objectively. The first chapter should include the title in Turkish and English, an unstructured summary and key words. Source of all citations should be indicated. The entire text should not exceed 25 pages (A4, formatted as specified above).

### Letter to Editor

- 463 The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy  
*Terapötik Plazma Değişiminin COVID-19 Tedavisine Etkisi*  
Cansu GÖNCÜOĞLU, Fatma Nisa BALLI, Aygün BAYRAKTAR EKİNCİOĞLU

### Original Articles

- 465 Gas Chromatographic and Spectrophotometric Determination of Diclofenac Sodium, Ibuprofen, and Mefenamic Acid in Urine and Blood Samples  
*Gaz Kromatografisi ve Spektrofotometri Yöntemleriyle İdrar ve Kan Örneklerinde Diklofenak Sodyum, İbuprofen ve Mefenamik Asit Tayini*  
Nida S. JALBANI, Amber R. SOLANGI, Muhammad Yar KHUAWAR, Shahabuddin MEMON, Ranjhan JUNEJO, Ayaz Ali MEMON
- 474 Acetamidiprid-induced Cyto- and Genotoxicity in the AR42J Pancreatic Cell Line  
*AR42J Pankreas Hücre Hattında Asetamidiprid ile İndüklenen Sito- ve Genotoksiste*  
Mehtap KARA, Ezgi ÖZTAŞ, Gül ÖZHAN
- 480 Determination of the Genetic Relationships Among *Salvia* Species by RAPD and ISSR Analyses  
*Salvia Türleri Arasındaki Genetik İlişkilerin RAPD ve ISSR Analizleriyle Belirlenmesi*  
Serap SUNAR, Mustafa KORKMAZ, Burcu SİĞMAZ, Güleray AĞAR
- 486 Design and *In Vitro* Characterization of Orally Disintegrating Modified Release Tablets of Naproxen Sodium  
*Naproxen Sodyumun Ağızda Dağılan Değiştirilmiş Salım Tabletlerinin Tasarımı ve İn Vitro Karakterizasyonu*  
Amjad HUSSAIN, Maham MISBAH, Nasir ABBAS, Muhammad IRFAN, Muhammad Sohail ARSHAD, Rahat SHAMIM, Nadeem Irfan BUKHARI, Faisal MAHMOOD
- 492 Formulation and *In Vitro* Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-Solvent Evaporation Technique  
*Emülsiyon-Çözücü Buharlaştırma Tekniği ile Hazırlanan Telmisartan Nanopartiküllerinin Formülasyonu ve İn Vitro Değerlendirilmesi*  
Naile ÖZTÜRK, Aslı KARA, İmran VURAL
- 500 Antimicrobial Activities of Some Pyrazoline and Hydrazone Derivatives  
*Bazı Pirazolin ve Hidrazon Türevlerinin Antimikrobiyal Aktiviteleri*  
Begüm EVRANOS AKSÖZ, Suna Sibel GÜRPINAR, Müjde ERYILMAZ
- 506 *In Vitro* Investigation of the Effects of Imidacloprid on AChE, LDH, and GSH Levels in the L-929 Fibroblast Cell Line  
*L929 Fibroblast Hücre Hattında İmidoklorit Etkisinin İn Vitro Araştırılması*  
Çiğdem SEVİM, Ali TAGHİZADEHGHAEHJOUGHİ, Mehtap KARA
- 511 Antimicrobial Potential of Bioactive Metabolites and Silver Nanoparticles from *Bacillus* spp. and of Some Antibiotics Against Multidrug Resistant *Salmonella* spp.  
*Bacillus spp.'nin Biyoaktif Metabolitleri ile Gümüş Nanopartikülleri ve Çoklu İlaç Direncine Karşı Bazı Antibiyotiklerin Antimikrobiyal Potansiyelleri*  
Bukola Christianah ADEBAYO-TAYO, Oluwadara EKUNDAYO-OBABA, Olutayo Israel FALODUN
- 523 Simultaneous Determination of Hydrochlorothiazide and Irbesartan from Pharmaceutical Dosage Forms with RP-HPLC  
*Farmasötik Dozaj Formlarında TF-YPSK ile Hidroklorotiyazid ve İrbesartanın Eş Zamanlı Tayini*  
Sevinç KURBANOĞLU, Aysu YARMAN
- 528 Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of *Lysimachia verticillaris* L. and Isolation of the Major Compounds  
*Lysimachia verticillaris L.'nin Kolinesteraz ve Tirozinaz İnhibitör Etki Potansiyeli ve Antioksidan Kapasitesi ile Ana Bileşiklerinin İzolasyonu*  
Ufuk ÖZGEN, Sıla Özlem ŞENER, Karel ŠMEJKAL, Jiri VACLAVIK, Fatma Sezer ŞENOL DENİZ, İlkay ERDOĞAN ORHAN, Emil SVAJDLENKA, Ahmet C. GÖREN, Milan ŽEMLIČKA
- 535 Determination of the Physicochemical Properties of Piroxicam  
*Piroksikamın Fizikokimyasal Özelliklerinin Belirlenmesi*  
Mustafa ÇELEBİER, Merve NENNİ, Ozan KAPLAN, Emrah AKGEYİK, Mustafa Sinan KAYNAK, Selma ŞAHİN
- 542 Investigation of Pectin-Hydroxypropyl Methylcellulose-Coated Floating Beads for Pulsatile Release of Piroxicam  
*Pektin-Hidroksipropil Metilselüloz Kaplı Yüzer Mikro Küreciklerin Piroksikamın Pulsatil Salımı Açısından Araştırılması*  
Dipali KAMBLE, Dilesh SINGHAVI, Shrikant TAPADIA, Shagufta KHAN



---

# TURKISH

---

# JOURNAL OF PHARMACEUTICAL SCIENCES

---

## CONTENTS

- 549 Citral Protects Human Endothelial Cells against Hydrogen Peroxide-induced Oxidative Stress  
*Sitral, İnsan Endotel Hücrelerini Hidrojen Peroksitin Neden Olduğu Oksidatif Strese Karşı Korur*  
Leila SAFAEIAN, Seyed Ebrahim SAJJADI, Hossein MONTAZERI, Farzaneh OHADI, Shaghayegh JAVANMARD
- 555 Tualang Honey Ameliorates Hypoxia-induced Memory Deficits by Reducing Neuronal Damage in the Hippocampus of Adult Male Sprague Dawley Rats  
*Tualang Balı, Yetişkin Erkek Sprague Dawley Sıçanlarının Hipokampusundaki Nöronal Hasarı Azaltarak Hipoksiye Bağlı Bellek Kayıplarını İyileştiriyor*  
Entesar Yaseen Abdo QAID, Rahimah ZAKARIA, Nurul Aiman MOHD YUSOF, Shaida Fariza SULAIMAN, Nazlahshaniza SHAFIN, Zahiruddin OTHMAN, Asma Hayati AHMAD, Che Badariah ABD AZIZ, Sangu MUTHURAJU
- Review**
- 565 Novel Targets for Antimicrobials  
*Antimikrobialler İçin Yeni Hedefler*  
Suchita GUPTA, Vaishali Ravindra UNDALE, Kedar LAKHADIVE

PUBLICATION NAME	Turkish Journal of Pharmaceutical Sciences
TYPE OF PUBLICATION	Vernacular Publication
PERIOD AND LANGUAGE	Bimonthly-English
OWNER	Erdoğan ÇOLAK on behalf of the Turkish Pharmacists' Association
EDITOR-IN-CHIEF	Prof.Terken BAYDAR, Ph.D.
ADDRESS OF PUBLICATION	Turkish Pharmacists' Association, Mustafa Kemal Mah 2147.Sok No:3 06510 Çankaya/ Ankara, TURKEY

# TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES

Volume: 17, No: 5, Year: 2020

## CONTENTS

### Letter to Editor

- The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy  
Cansu GÖNCÜOĞLU, Fatma Nisa BALLI, Aygün BAYRAKTAR EKİNCİOĞLU .....463

### Original Articles

- Gas Chromatographic and Spectrophotometric Determination of Diclofenac Sodium, Ibuprofen, and Mefenamic Acid in Urine and Blood Samples  
Nida S. JALBANI, Amber R. SOLANGI, Muhammad Yar KHUAWAR, Shahabuddin MEMON, Ranjhan JUNEJO, Ayaz Ali MEMON .....465
- Acetamidopirid-induced Cyto- and Genotoxicity in the AR42J Pancreatic Cell Line  
Mehtap KARA, Ezgi ÖZTAŞ, Gül ÖZHAN .....474
- Determination of the Genetic Relationships Among *Salvia* Species by RAPD and ISSR Analyses  
Serap SUNAR, Mustafa KORKMAZ, Burcu SİĞMAZ, Güleray AĞAR .....480
- Design and *In Vitro* Characterization of Orally Disintegrating Modified Release Tablets of Naproxen Sodium  
Amjad HUSSAIN, Maham MISBAH, Nasir ABBAS, Muhammad IRFAN, Muhammad Sohail ARSHAD, Rahat SHAMIM, Nadeem Irfan BUKHARI, Faisal MAHMOOD .....486
- Formulation and *In Vitro* Evaluation of Telmisartan Nanoparticles Prepared by Emulsion-solvent Evaporation Technique  
Naile ÖZTÜRK, Aslı KARA, İmran VURAL .....492
- Antimicrobial Activities of Some Pyrazoline and Hydrazone Derivatives  
Begüm EVRANOS AKSÖZ, Suna Sibel GÜRPINAR, Müjde ERYILMAZ .....500
- In Vitro* Investigation of the Effects of Imidacloprid on AChE, LDH, and GSH Levels in the L-929 Fibroblast Cell Line  
Çiğdem SEVİM, Ali TAGHİZADEHGHALEHJOUGHİ, Mehtap KARA .....506
- Antimicrobial Potential of Bioactive Metabolites and Silver Nanoparticles from *Bacillus* spp. and of Some Antibiotics Against Multidrug Resistant *Salmonella* spp.  
Bukola Christianah ADEBAYO-TAYO, Oluwadara EKUNDAYO-OBABA, Olutayo Israel FALODUN .....511
- Simultaneous Determination of Hydrochlorothiazide and Irbesartan from Pharmaceutical Dosage Forms with RP-HPLC  
Sevinç KURBANÖĞLU, Aysu YARMAN .....523
- Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of *Lysimachia verticillaris* L. and Isolation of the Major Compounds  
Ufuk ÖZGEN, Sıla Özlem ŞENER, Karel ŠMEJKAL, Jiri VACLAVIK, Fatma Sezer ŞENOL DENİZ, İlkay ERDOĞAN ORHAN, Emil SVAJDLENKA, Ahmet C. GÖREN, Milan ŽEMLIČKA .....528
- Determination of the Physicochemical Properties of Piroxicam  
Mustafa ÇELEBİER, Merve NENNİ, Ozan KAPLAN, Emrah AKGEYİK, Mustafa Sinan KAYNAK, Selma ŞAHİN .....535
- Investigation of Pectin-Hydroxypropyl Methylcellulose-Coated Floating Beads for Pulsatile Release of Piroxicam  
Dipali KAMBLE, Dilesh SINGHAVI, Shrikant TAPADIA, Shagufta KHAN .....542
- Citral Protects Human Endothelial Cells Against Hydrogen Peroxide-induced Oxidative Stress  
Leila SAFAEIAN, Seyed Ebrahim SAJJADI, Hossein MONTAZERI, Farzaneh OHADI, Shaghayegh JAVANMARD .....549
- Tualang Honey Ameliorates Hypoxia-induced Memory Deficits by Reducing Neuronal Damage in the Hippocampus of Adult Male Sprague Dawley Rats  
Entesar Yaseen Abdo QAID, Rahimah ZAKARIA, Nurul Aiman MOHD YUSOF, Shaida Fariza SULAIMAN, Nazlahshaniza SHAFIN, Zahiruddin OTHMAN, Asma Hayati AHMAD, Che Badariah ABD AZIZ, Sangu MUTHURAJU .....555
- ### Review
- Novel Targets for Antimicrobials  
Suchita GUPTA, Vaishali Ravindra UNDALE, Kedar LAKHADIVE .....565